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Abstract
Objectives—To address concerns regarding increased risk of prostate cancer (PrCA) among 
Angiotensin Receptor Blocker users, we used national retrospective data from the Department of 
Veterans Affairs (VA) through the Veterans Affairs Informatics and Computing Infrastructure 
(VINCI).
Methods—We identified a total of 543,824 unique Veterans who were classified into either ARB 
treated or not-treated in 1:15 ratio. The two groups were balanced using inverse probability of 
treatment weights. A double-robust cox-proportional hazards model was used to estimate the 
hazard ratio for PrCA incidence. To evaluate for a potential Gleason score stage migration we 
conducted weighted Cochrane-Armitage test.
Results—Post weighting, the rates of PrCA in treated and not-treated groups were 506 (1.5%) 
and 8,269 (1.6%), respectively; representing a hazard ratio of (0.91, p-value 0.049). There was no 
significant difference in Gleason scores between the two groups.
Conclusions—We found a small, but statistically significant, reduction in the incidence of 
clinically detected PrCA among patients assigned to receive ARB with no countervailing effect on 
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degree of differentiation (as indicated by Gleason score). Findings from this study support FDA’s 
recent conclusion that ARB use does not increase risk of incident PrCA.
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Angiotensin Receptor Blockers; Prostate Cancer; Department of Veterans Affairs; Inverse 
Probability of Treatment Weight; Propensity Score; Survival analysis; Cancer Registry; Drug 
Safety
Introduction
Angiotensin receptor blocker (ARB) use was reported to increase the risk for solid-cancers.1 
For prostate cancer (PrCA) the ARB-treated cohort had a meta-analytic risk ratio of 1.15 
(C.I., 0.99,1.34, p = 0.076), that barely missed statistical significance.1 The increased risk 
was not confirmed in subsequent studies or by the Food and Drug Administration (FDA)2–6. 
In fact Uemura et.al., have found evidence that ARBs may have anti-proliferative effect of 
PrCA cells.7–11 Thus, the residual concerns for increased risk of PrCA among ARB users is 
minimal, but since the majority of the follow-up studies were not done on individual level 
data, i.e. were meta-analysis, and when done with individual level data were based mainly 
on claims data from outside the United States, we decided to evaluate the safety signal in the 
Department of Veterans Affairs (VA).
The VA has provided medical care to >8 million male individuals. The VA researchers have 
access to claims data linked with individual patient level data from electronic medical 
records that includes pharmacy dispensation, laboratory results, cancer registry. This data 
when used with appropriate epidemiological research methods is able to provide valuable 
insight into the real-world relationship between ARB use and risk of prostate cancer.
Methods
We conducted an intention-to-treat (ITT) inverse-probability-of-treatment-weighted 
(IPTW)12 retrospective cohort study to evaluate the impact of ARB prescribed for clinically 
indicated reasons on the incidence and histopathological grade of clinically detectable PrCA. 
The IPTW method is a propensity-score based method12 that is able to correct 
mathematically for baseline differences (measured covariates) between comparison groups: 
in this retrospective study, IPTW is expected to balance differences in measured baseline 
covariates between the group that was assigned to receive ARB and the group that was 
assigned to not receive ARB. Regulatory approvals were obtained from the Institutional 
Review Board (IRB) of the William J.B. Dorn VAMC, the VA National Data Systems, the 
VA Patient Care Services and the Veterans Affairs Informatics and Computing 
Infrastructure (VINCI). We obtained linked individual-level data on all eligible Veteran 
patients from 1999 to 2011 from VA’s Central Cancer Registry (CCR), MedSAS, Decision 
Support System (DSS),13 Vital status file, health factors (for tobacco exposure),14 and the 
Corporate Data Warehouse (CDW).15
We based our cohort selection method on the methods developed by Hernan et.al.16 –where 
the recruitment process of a clinical trial was simulated using observational data. We 
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simulated a randomly allocated intention to treat experiment that randomly assigns recruited 
patients to either ARB (treated) or non-ARB (not-treated) groups in 1:15 ratio continuously 
across calendar years 2003–2009 with a-priori end-point of December 31st 2010. The cohort 
selection was performed in blocks of calendar years and then all individuals were pooled to 
form the final definitive cohort. As a first step, we identified new users of ARB between 
2003 and 2009, who did not have an ARB dispensing in the previous years starting from 
1999.
We first created the 2003 cohort. For patients receiving their first ARB dispensation in 2003, 
their start date of follow-up was defined as the closest date of outpatient VA clinician 
encounter ≤2 weeks before start date of ARB dispensing, ‘assigned to receive treatment’ 
(treated). If a patient was found to have started ARB without a corresponding VA clinical 
encounter, that patient was excluded. The rationale for this exclusion was that it is unlikely 
for a patient to start a new ARB treatment without a corresponding encounter with a 
clinician, except in such instances as a Veteran filling a non-VA prescription at a VA 
pharmacy. Including such individuals may introduce bias from missing information on 
comorbidity as the predominant care may be at a non-VA setting and thus not captured by 
VA electronic medical record system. The comparator groups, i.e. ‘assigned to receive no-
treatment’ (not-treated) were 15-randomly selected individuals who had a VA clinician 
encounter in the year 2003, but did not receive ARB in the year of 2003 (from Jan 2003– 
Dec 2003). The start date of follow-up for not-treated group was a randomly selected date of 
their many respective actual clinical encounters in the year 2003. We achieved this by 
selecting the date corresponding to the lowest seed per person for that year, generated using 
SAS 9.2 Cary, NC function Proc RANUNI).
We then repeated this cohort selection method for the years 2004–2009, except that all 
patients who were already selected into prior year cohorts were not eligible to be selected 
into subsequent year cohorts. Finally, we pooled all 7-cohorts to form a single definitive 
cohort that was analyzed. Thus, a single patient was eligible to be represented in the 
definitive cohort only once. Baseline covariates were identified based on the date of start of 
follow-up.
We excluded from the staged selection process patients who were documented to have 
cancer in VA Central Cancer Registry (excluding non-melanoma skin cancer); had not 
established VA clinical, pharmacy and laboratory care at least 6-months prior to start date; 
those without information in VA health factor file for tobacco use; those with age < 55 or > 
74 years (to ensure homogeneity between the two group, as both PrCA and ARBs are related 
to age); and those in the not-treated group who had propensity scores of either less than the 
5th percentile or greater than 95th percentile of the treatment group (to reduce instability of 
IPTW).17,18 All selected patients were then followed till the first of either the last date of 
VA healthcare benefit, death, date of diagnosis of prostate cancer, or December 31st 2010 
(a-priori determined end-point), whichever came first.
We computed propensity scores using all variables listed in Table 1 and weighted the cohort 
using stabilized IPTW. The weighted cohort may now be expected to be similar to a cohort 
obtained from a random allocation experiment.19 Incidence curves were drawn for both 
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types of exposures and for the absolute difference between exposures (Figure 1). Double-
robust regression with IPTW after checking for Cox-Proportionality assumption was used to 
derive weighted hazard ratios (HR) with 95% confidence intervals. To evaluate if there was 
a difference in Gleason scores for the PrCAs diagnosed in the two groups, we conducted 
weighted CochranArmitage test for trend, as Gleason score is ordinal. All reported p-values 
are two-sided and all analyses on categorical data used exact methods when possible.
Results
For the years 2003 to 2009 the un-weighted cohorts had respectively: 95,568; 99,664; 
81,600; 70,944; 67,616; 66,080 and 62,352 individual patients. This formed a pooled 
unweighted cohort of 543,824 individuals. Weighting with IPTW resulted in excellent 
balance for all 54 variables that was used to compute propensity to receive treatment (Table 
1). Propensity to receive treatment was most impacted by diabetes mellitus, serum 
creatinine, current use of insulin, use of Angiotensin Converting Enzyme inhibitors (ACEi), 
body mass index [BMI=weight(kg)/height(m)2], chronic renal failure, congestive heart 
failure, hypertension and low density lipoprotein; and least impacted by race, ethnicity, 
income, insurance status and religion. As expected, baseline PSA levels, prior utilization of 
PSA-based testing, prior prostate biopsy or use of 5-α-reductase inhibitor were not found to 
significantly impact the decision to assign ARB.
The weighted definitive cohort had, in treated and not-treated arms respectively 34,275 and 
509,922; with PrCA rates of 506 (1.5%) and 8,269 (1.6%). The weighted hazard ratio (HR) 
for ARB was 0.91 (95% C.I. 0.84 to 0.99, p-value = 0.049). All independent HRs are 
reported in Table 2. Current smokers had a HR of 1.69 (95% C.I., 1.38, 2.06, p < 0.001) 
compared to never smokers, while patients with extremes of BMI where less likely to be 
diagnosed with PrCA compared to patients with normal BMI. We classified Gleason score 
based on aggressiveness into either <7, =7 or >7. The distribution of Gleason scores in the 
treated group was 225 (46.9%), 178 (37.1%) and 77 (16%); this was similar to the not-
treated group 3,580 (46.3%), 3,006 (38.9%) and 1,142 (14.8%), with no statistical 
difference.
Discussion
In this national cohort of veteran patients we observed a slight statistically significant 
reduction in the rate of clinically detected PrCA among patients assigned to receive ARB. 
An interesting incidental finding is that, this cancer reduction effect was not associated with 
PrCA grade migration as is expected in the 5-α reductase inhibitor clinical trials20. The 
independent pathways by which ARBs are proposed to exert anti-cancer effect may be the 
reason for the lack of grade progression.7,8,10
In our review of literature, we found that the biological evidence supporting the increased 
risk of PrCA from use of ARB is limited. Some explanations are related to imbalance in the 
local tissue level effect of Angiotensin II on inflammation and carcinogenesis. Angiotensin 
II influences the regulation of cell proliferation, angiogenesis, tissue repair, healing and 
development, and an imbalance may alter the risk of proliferation of cancer cells.21–23 
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Unlike angiotensin converting enzyme inhibitors, ARBs do not suppress the production of 
Angiotensin II: thus in the presence ARB induced Angiotensin type-I receptor blockade, it 
maybe speculated that circulating Angiotensin II may have enhanced Angiogenesis or pro-
inflammatory activity; either directly or through Angiotensin type-II receptors.24,25 
However, many researchers suggest a cancer protective effect.
Cancer protective effects of ARBs reported by other researchers include: reduction of basal 
and squamous cell carcinomas,26 lung cancer metastatic burden,27 and to improve overall 
lung cancer survival.28 Specifically for PrCA, Candesartan has been shown to decrease PSA 
levels, improve performance status and decrease the need for analgesics among castration-
resistant prostate cancer (CRPC) patients.10 Activation of AT1R has been shown to 
stimulate the proliferation of prostatic adenocarcinoma,9 while blockade of locally expressed 
AT1 receptors by ARBs are reported to modulate local growth factors and cytokine 
expression in tumor tissues (local RAS).29 In addition to the local RAS for cancer 
prevention, a prostate tissue-specific pathway may exist that would down-regulate the 
expression of androgen receptors.11
The study limitations are many, but have been addressed to a large extent by careful study 
design and analysis. While computing propensity scores we have include many measured 
confounders and many instrumental variables. By balancing instrumental variables, we hope 
that we will be able to balance many unmeasured variables as well. To avoid errors due to 
missing information on Veterans who only receive part of their care in the VA, we required 
all individuals to have already established care in the VA at least 6-months prior to start of 
follow-up; still there may be some individuals who might receive their ARB dispensation 
from a non-VA pharmacy. A research study using Veteran only data may not be easily 
generalizable to non-Veteran population, and this concern is common to all research 
involving data from the VA. We conducted analysis by strictly adhering to the ITT 
paradigm, i.e. although we had information on treatment patterns during interval follow-up 
these data were not analyzed and switches in treatment/compliance was not taken into 
account. Also not analyzed were cumulative exposures, as these may be affected by the 
violation of the ITT assumption. Because our purpose was to evaluate the class effect of 
ARB on PrCA, we did not conduct sub-analyses stratified by ARB-subtype.
The findings of our study are insufficient to recommend the use of ARB as a PrCA 
chemoprevention modality. However, our finding of an ARB-related weak PrCA protective 
effect helps assuage any residual concerns of increased PrCA risk1 and supports the 
conclusions of the FDA.30
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Table 1
Distribution of baseline covariates between treated and untreated before and after weighting with inverse 
probability of treatment weights
TABLE Treated vs. Untreated
(Un-weighted)
Treated vs. Untreated (Weighted)
Number of patients 33,989 vs. 509,835 34,275 vs. 509,922
Age 63.6 ± (5.5) vs. 63.6 ± (5.6) 63.6 ± (5.5) vs. 63.6 ± (5.6)
Male 33,989 (100%) vs. 509,835 (100%) 34,275 (100%) vs. 509,922 (100%)
Race
  White (European American) 27,656 (81.4%) vs. 421,829 (82.7%) 28,444 (83%) vs. 421,484 (82.7%)
  African American 4,887 (14.4%) vs. 67,033 (13.1%) 4,404 (12.8%) vs. 67,414 (13.2%)
  Hawaiian or Pacific Islander 176 (0.5%) vs. 2,455 (0.5%) 163 (0.5%) vs. 2,467 (0.5%)
  Mixed European- and African- American race 437 (1.3%) vs. 6,943 (1.4%) 486 (1.4%) vs. 6,921 (1.4%)
  Mixed other races 566 (1.7%) vs. 8,183 (1.6%) 543 (1.6%) vs. 8,200 (1.6%)
  Other races 267 (0.8%) vs. 3,392 (0.7%) 235 (0.7%) vs. 3,437 (0.7%)
Hispanic Ethnicity 1,825 (5.4%) vs. 26,208 (5.1%) 1,657 (4.8%) vs. 26,270 (5.2%)
Body Mass Index 31.5 ± (5.7) vs. 30.4 ± (5.4) 30.4 ± (5.3) vs. 30.5 ± (5.5)
Dual benefit patient (VA and Medicare) 18,324 (53.9%) vs. 270,814 (53.1%) 18,107 (52.8%) vs. 271,133 (53.2%)
Religion
  Catholic 8,773 (25.8%) vs. 130,919 (25.7%) 8,563 (25%) vs. 130,970 (25.7%)
  Protestant 20,857 (61.4%) vs. 314,581 (61.7%) 21,245 (62%) vs. 314,517 (61.7%)
  Jewish 448 (1.3%) vs. 5,965 (1.2%) 397 (1.2%) vs. 6,017 (1.2%)
  Other 3,911 (11.5%) vs. 58,370 (11.4%) 4,069 (11.9%) vs. 58,419 (11.5%)
Tobacco use
    Current user 17,811 (52.4%) vs. 277,553 (54.4%) 18,749 (54.7%) vs. 276,935 (54.3%)
    Former user 15,227 (44.8%) vs. 218,653 (42.9%) 14,553 (42.5%) vs. 219,269 (43%)
    Never user 951 (2.8%) vs. 13,629 (2.7%) 973 (2.8%) vs. 13,719 (2.7%)
Alcohol Abuse 3,762 (11.1%) vs. 59,006 (11.6%) 4,297 (12.5%) vs. 58,870 (11.5%)
Substance Abuse 2,327 (6.8%) vs. 34,173 (6.7%) 2,594 (7.6%) vs. 34,252 (6.7%)
Baseline Comorbidity
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TABLE Treated vs. Untreated
(Un-weighted)
Treated vs. Untreated (Weighted)
    Diabetes Mellitus 12,590 (37%) vs. 130,146 (25.5%) 8,991 (26.2%) vs. 133,898 (26.3%)
    Essential Hypertension 33,484 (98.5%) vs. 508,953 (99.8%) 34,151 (99.6%) vs. 508,431 (99.7%)
    Myocardial infarction 720 (2.1%) vs. 7,688 (1.5%) 520 (1.5%) vs. 7,885 (1.5%)
    Cardiac dysrhythmia 5,863 (17.2%) vs. 78,794 (15.5%) 5,252 (15.3%) vs. 79,377 (15.6%)
    Congestive Heart Failure 3,300 (9.7%) vs. 26,376 (5.2%) 1,845 (5.4%) vs. 27,847 (5.5%)
    Acute Cerebrovascular disease 1,674 (4.9%) vs. 23,130 (4.5%) 1,639 (4.8%) vs. 23,249 (4.6%)
    Chronic Obstructive Pulmonary Disease 7,373 (21.7%) vs. 108,041 (21.2%) 7,375 (21.5%) vs. 108,249 (21.2%)
    Asthma 2,042 (6%) vs. 26,781 (5.3%) 1,753 (5.1%) vs. 27,031 (5.3%)
    Chronic Renal Failure 2,169 (6.4%) vs. 13,934 (2.7%) 960 (2.8%) vs. 15,096 (3%)
    Ulcerative Colitis 280 (0.8%) vs. 4,423 (0.9%) 307 (0.9%) vs. 4,413 (0.9%)
    Rheumatoid Arthritis 701 (2.1%) vs. 11,358 (2.2%) 743 (2.2%) vs. 11,304 (2.2%)
    Benign Prostatic Hyperplasia 7,011 (20.6%) vs. 110,520 (21.7%) 7,345 (21.4%) vs. 110,190 (21.6%)
    Human Immunodeficiency Virus 85 (0.3%) vs. 1,116 (0.2%) 99 (0.3%) vs. 1,130 (0.2%)
    Hepatitis B 619 (1.8%) vs. 8,709 (1.7%) 605 (1.8%) vs. 8,756 (1.7%)
    Hepatitis C 1,670 (4.9%) vs. 23,363 (4.6%) 1603 (4.7%) vs. 23,476 (4.6%)
    Mood disorder 9,232 (27.2%) vs. 132,832 (26.1%) 9,162 (26.7%) vs. 133,239 (26.1%)
    Schizophrenia 928 (2.7%) vs. 14,968 (2.9%) 1,179 (3.4%) vs. 14,911 (2.9%)
    Personality Disorder 547 (1.6%) vs. 8,191 (1.6%) 656 (1.9%) vs. 8,198 (1.6%)
    Epilepsy 679 (2%) vs. 10,674 (2.1%) 789 (2.3%) vs. 10,647 (2.1%)
    History of Coma 144 (0.4%) vs. 1,782 (0.3%) 136 (0.4%) vs. 1,808 (0.4%)
    History of suicidality 165 (0.5%) vs. 2,274 (0.4%) 170 (0.5%) vs. 2,287 (0.4%)
Baseline Medication
    Angiotensin Converting Enzyme inhibitor 14,420 (42.4%) vs. 165,276 (32.4%) 11356 (33.1%) vs. 168519 (33%)
    Antidepressants 5,693 (16.7%) vs. 78,708 (15.4%) 5,236 (15.3%) vs. 79,159 (15.5%)
    Beta blockers 11,051 (32.5%) vs. 148,579 (29.1%) 9,577 (27.9%) vs. 149,555 (29.3%)
    Calcium channel blocker 4,636 (13.6%) vs. 58,201 (11.4%) 3,637 (10.6%) vs. 58,839 (11.5%)
    Glucocorticoids 1,286 (3.8%) vs. 15,558 (3.1%) 989 (2.9%) vs. 15,795 (3.1%)
    Insulin 4,052 (11.9%) vs. 27,145 (5.3%) 1,925 (5.6%) vs. 29,310 (5.7%)
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TABLE Treated vs. Untreated
(Un-weighted)
Treated vs. Untreated (Weighted)
    Statins 2,772 (8.2%) vs. 34,565 (6.8%) 2,268 (6.6%) vs. 35,002 (6.9%)
    5-alpha-reductase inhibitor 733 (2.2%) vs. 10,686 (2.1%) 706 (2.1%) vs. 10,704 (2.1%)
    Thiazide diuretics 12,368 (36.4%) vs. 150,127 (29.4%) 9,838 (28.7%) vs. 152,233 (29.9%)
Baseline laboratory results
    Prostate specific antigen 1.8 ± (2) vs. 1.8 ± (2.9) 1.8 ± (2.7) vs. 1.8 ± (2.9)
    Alanine amino transferase 33.3 ± (18.9) vs. 32.8 ± (17.6) 32.9 ± (17.6) vs. 32.8 ± (18.1)
    Asparatate aminotransferase 28.2 ± (16.5) vs. 28.2 ± (13.8) 28.4 ± (17.4) vs. 28.2 ± (14)
    International Normalized Ratio 1.4 ± (0.5) vs. 1.4 ± (0.5) 1.4 ± (0.5) vs. 1.4 ± (0.5)
    Platelet count 158.3 ± (32.9) vs. 157.2 ± (30.8) 157 ± (29.8) vs. 157.2 ± (31)
    Albumin 4.1 ± (0.4) vs. 4.1 ± (0.3) 4.1 ± (0.4) vs. 4.1 ± (0.3)
    High Density Lipoprotein 42.7 ± (7.5) vs. 43.3 ± (7.4) 43.3 ± (7.6) vs. 43.2 ± (7.4)
    Hemoglobin 14.5 ± (1.4) vs. 14.6 ± (1.2) 14.6 ± (1.3) vs. 14.6 ± (1.2)
    Low Density Lipoprotein 103.4 ± (30.3) vs. 106.7 ± (28.6) 106.5 ± (30.5) vs. 106.5 ± (28.6)
    Potassium 4.3 ± (0.5) vs. 4.3 ± (0.4) 4.3 ± (0.4) vs. 4.3 ± (0.4)
    Creatinine 1.2 ± (0.5) vs. 1.1 ± (0.3) 1.1 ± (0.3) vs. 1.1 ± (0.3)
    Total Cholesterol 175.5 ± (38.7) vs. 177.1 ± (36.1) 177 ± (37.8) vs. 177 ± (36.3)
    Triglycerides 167.2 ± (91.7) vs. 160.2 ± (85) 160.4 ± (86.5) vs. 160.6 ± (85.4)
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Table 2
Adjusted hazard ratios for Prostate Cancer occurrence, double-robust Inverse Probability treatment weighted 
survival analysis
Variables Hazard Ratio
Angiotensin Receptor Blocker 0.91 (0.84 to 1, p-value 0.049)
Age group (Reference '>=70')
  65 to 70 years 1.03 (0.97 to 1.1, p-value 0.3974)
  60 to 65 1.51 (1.42 to 1.61, p-value <.0001)
  < 60 1.03 (0.97 to 1.1, p-value 0.3974)
Race (reference 'White' or European American)
  African American 2.44 (2.32 to 2.56, p-value <.0001)
  Hawaiian or Pacific Islander 0.86 (0.59 to 1.26, p-value 0.4397)
  Mixed European- and African- American race 1.79 (1.58 to 2.03, p-value <.0001)
  Mixed other races 1.09 (0.81 to 1.46, p-value 0.5655)
  Other races 1.09 (0.81 to 1.46, p-value 0.5655)
Hispanic ethnicity 1.19 (1.09 to 1.31, p-value 0.0001)
Smoker (reference 'Never')
  Current 1.69 (1.38 to 2.06, p-value <.0001)
  Former 1.58 (1.29 to 1.93, p-value <.0001)
Body Mass Index 0.99 (0.98 to 0.99, p-value <.0001)
Diabetes Mellitus 0.99 (0.94 to 1.05, p-value 0.8303)
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